Skip to main content
Premium Trial:

Request an Annual Quote

Two RNAi-Related Patent Applications Published by the USPTO

Premium

Title: Nucleic Acid and Corresponding Protein Entitled 98P4B6 Useful in Treatment and Detection of Cancer.

Number: 20050086707.

Filed: June 4, 2004.

Inventor: Aya Jakobovits, Agensys.

The patent application, its abstract states, cover "antibodies and molecules derived there from that bind to novel STEAP-1 protein, and variants thereof, … wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in [certain] cancers.

"Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer," the abstract notes. "The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization."

The patent application specifically claims a STEAP-1 siRNA.


Title: Methods and Compositions for siRNA Expression.

Number: 20050089902.

Filed: Sept 1, 2004.

Lead Inventor: Lianxing Zheng, Scripps Research Institute.

The invention, the patent application's abstract states, comprises "one-step methods for generating siRNA expression cassettes. … Expression cassettes useful for siRNA are also provided."

Specifically, the application claims a "method for producing two complementary strands of a tripartite DNA comprising a 5' amplification primer binding site and a 3' amplification primer binding site with an intervening sequence between the two sites." This method involves "providing a polymerase extension reaction mixture comprising the following reagents: a) an initial double-stranded DNA comprising a left end comprising a 5' amplification primer binding site; and a right end complementary to a 3' end of an intervening linking primer; b) the intervening linking primer comprising: a 5' end complementary to a left end of a terminal DNA; a 3' end complementary to the right end of the initial DNA; and an intervening sequence between the 5' end and the 3' end; c) the terminal double-stranded DNA comprising a right end that is a 3' amplification primer binding site; and a left end complementary to the 5' end of the intervening linking primer; d) DNA polymerase and components sufficient for a polymerase chain reaction; reacting the reagents of the mixture in at least two thermocycles, wherein the first cycle comprises a melting temperature to denature double-stranded DNA; an initial annealing temperature to anneal the intervening linking primer to a strand of the initial double-stranded DNA; and an extension temperature for the polymerase to extend a 3' end of the strand of the initial double-stranded DNA using the intervening linking primer as a template to produce an intermediate product comprising the strand of the initial double-stranded DNA and a complement of the intervening linking primer; and the second cycle comprises a melting temperature to denature double-stranded DNA; an annealing temperature to anneal the intermediate product to a strand of the terminal double-stranded DNA; and an extension temperature for the polymerase to extend the 3' end of the intermediate product using the strand of the terminal double-stranded DNA as a template to produce a single-stranded tripartite DNA comprising the strand of the initial double-stranded DNA, the complement of the intervening linking primer, and the complement of the strand of the terminal double-stranded DNA sequences; and to extend the 3' end of the strand of the terminal double-stranded DNA using the intermediate product as a template to produce the complement of the single-stranded tripartite DNA."

The application further claims a kit for generating a siRNA polynucleotide, with "the kit comprising a) an initial double-stranded DNA comprising a left end comprising a 5' amplification primer binding site; and a right end complementary to a 3' end of an intervening linking primer; b) the intervening linking primer comprising: a 5' end complementary to a left end of a terminal DNA; and a 3' end complementary to the right end of the initial DNA; an intervening sequence between the 5' end and the 3' end; c) the terminal double-stranded DNA comprising a right end that is a 3' amplification primer binding site; and a left end complementary to the 5' end of the intervening linking primer; d) a 5' amplification primer; and e) a 3' amplification primer."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.